The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics and outcomes of patients diagnosed with DNMT3A mutated acute myeloblastic leukemia.
 
Daniel Rivera
No Relationships to Disclose
 
Hagop M. Kantarjian
Honoraria - Abbvie; Actinium Pharmaceuticals; Agios; Amgen; ARIAD; Bristol-Myers Squibb; Immunogen; Orsenix; Pfizer; Takeda
Research Funding - Abbvie (Inst); Agios (Inst); Agios (Inst); Agios (Inst); Amgen (Inst); ARIAD (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst)
 
Tapan M. Kadia
Consulting or Advisory Role - Abbvie/Genentech; Agios; Jazz Pharmaceuticals; Novartis; Pfizer
Research Funding - Amgen; Ascentage Pharma; Astellas Pharma; AstraZeneca; BiolineRx; Bristol-Myers Squibb; Celgene; Cyclacel; Genentech/Abbvie; Genfleet Therapeutics; Incyte; Jazz Pharmaceuticals; Pfizer; Sanofi
 
Naval Guastad Daver
Honoraria - Abbvie; Astellas Pharma; BMS; Immunogen; Incyte; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer
Consulting or Advisory Role - Abbvie; Agios; Amgen; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Immunogen; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Novartis; Otsuka; Pfizer; SERVIER; Sunesis Pharmaceuticals; Syndax; Trillium Therapeutics
Research Funding - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Immunogen; Incyte; Karyopharm Therapeutics; Nohla Therapeutics; Novartis; Pfizer; Servier; SOBI; Sunesis Pharmaceuticals
 
Courtney Denton Dinardo
Leadership - Notable Labs
Stock and Other Ownership Interests - Notable Labs
Honoraria - Abbvie; Agios; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Takeda
Consulting or Advisory Role - Abbvie; Agios; Celgene
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo
 
Nicholas James Short
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca
Research Funding - Astellas Pharma; Takeda
 
Musa Yilmaz
Research Funding - Daiichi Sankyo; Pfizer; Pfizer
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Pfizer; Takeda
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Celgene; Helsinn Healthcare
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb; Celgene; Helsinn Therapeutics; Jazz Pharmaceuticals
Research Funding - Abbvie; Amphivena; Astex Pharmaceuticals; Bristol-Myers Squibb; celgene; H3 Biomedicine; Helsinn Therapeutics; Merck; Novartis; Onconova Therapeutics
 
Marina Konopleva
Honoraria - Abbvie; Amgen; Amgen; Genentech; KisoJi Biotechnology; Roche; Stemline Therapeutics
Consulting or Advisory Role - AbbVie; Amgen; Forty Seven; Genentech/Roche; Janssen; KisoJi Biotechnology; KisoJi Biotechnology; Roche; Stemline Therapeutics
Research Funding - Abbvie (Inst); Ablynx (Inst); Agios (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Genentech (Inst); Lilly (Inst); Roche (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Eli LIlly- Research Funding; Issued/ Licensed; Novartis- PENDING; Reata pharmaceutical - Research Funding- (Issued, Licensed, Royalities); Reata pharmaceutical - Research Funding- (Issued, Licensed, Royalities)
 
Gautam Borthakur
Consulting or Advisory Role - Argenx; BiolineRx; BioTheryX; Catamaran Bio; Nkarta; Novartis; PTC Therapeutics; Takeda; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Arvinas (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BiolineRx (Inst); BioTheryX (Inst); Bristol-Myers Squibb (Inst); Cellestia Biotech (Inst); Cyclacel (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Scientific Affairs (Inst); Lilly (Inst); MedImmune (Inst); Mundipharma Research (Inst); Nkarta (Inst); Nkarta (Inst); Novartis (Inst); Oncoceutics (Inst); PTC Therapeutics (Inst); Ryvu Therapeutics (Inst); TCR2 Therapeutics (Inst); Treadwell Therapeutics (Inst); XBiotech (Inst)
 
Farhad Ravandi
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Jazz Pharmaceuticals; Novartis; Orsenix; Pfizer; Takeda
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Certara Inc; Jazz Pharmaceuticals; Orsenix; Syros Pharmaceuticals; Taiho Oncology; Taiho Oncology
Research Funding - Amgen; Bristol-Myers Squibb; Cellerant; Macrogenics; Selvita; Xencor